Nurix Therapeutics, Inc. $NRIX Shares Purchased by UBS Group AG

UBS Group AG lifted its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 16.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 423,425 shares of the company’s stock after purchasing an additional 60,879 shares during the quarter. UBS Group AG’s holdings in Nurix Therapeutics were worth $8,032,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Nurix Therapeutics by 32.5% in the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock valued at $112,862,000 after purchasing an additional 1,460,736 shares during the period. Vestal Point Capital LP boosted its position in shares of Nurix Therapeutics by 73.8% in the 3rd quarter. Vestal Point Capital LP now owns 3,475,000 shares of the company’s stock valued at $32,109,000 after purchasing an additional 1,475,000 shares during the period. Amova Asset Management Americas Inc. raised its stake in Nurix Therapeutics by 12.1% during the 3rd quarter. Amova Asset Management Americas Inc. now owns 1,557,479 shares of the company’s stock valued at $14,391,000 after acquiring an additional 168,205 shares during the last quarter. Millennium Management LLC raised its stake in Nurix Therapeutics by 64.3% during the 3rd quarter. Millennium Management LLC now owns 1,523,959 shares of the company’s stock valued at $14,081,000 after acquiring an additional 596,401 shares during the last quarter. Finally, Perceptive Advisors LLC raised its stake in Nurix Therapeutics by 268.7% during the 2nd quarter. Perceptive Advisors LLC now owns 1,096,985 shares of the company’s stock valued at $12,495,000 after acquiring an additional 799,432 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have commented on NRIX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $26.00 price objective on shares of Nurix Therapeutics in a research note on Thursday, April 23rd. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of Nurix Therapeutics in a research note on Monday, April 27th. BTIG Research reaffirmed a “buy” rating and set a $30.00 price objective on shares of Nurix Therapeutics in a research note on Monday. Wells Fargo & Company reduced their price objective on Nurix Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Thursday, April 9th. Finally, Royal Bank Of Canada upped their price objective on Nurix Therapeutics from $28.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Nurix Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $30.46.

Nurix Therapeutics Price Performance

NASDAQ NRIX opened at $15.51 on Tuesday. Nurix Therapeutics, Inc. has a 1-year low of $8.19 and a 1-year high of $22.50. The company has a market capitalization of $1.60 billion, a P/E ratio of -4.91 and a beta of 1.87. The business has a 50 day moving average price of $15.91 and a 200 day moving average price of $16.47.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Wednesday, April 8th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.03). Nurix Therapeutics had a negative net margin of 411.37% and a negative return on equity of 64.21%. The firm had revenue of $6.25 million during the quarter, compared to analysts’ expectations of $14.25 million. On average, research analysts expect that Nurix Therapeutics, Inc. will post -2.94 earnings per share for the current fiscal year.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,214 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $16.65, for a total transaction of $53,513.10. Following the sale, the insider owned 120,399 shares in the company, valued at approximately $2,004,643.35. This represents a 2.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Houte Hans Van sold 14,055 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total value of $233,313.00. Following the sale, the chief financial officer owned 37,592 shares in the company, valued at approximately $624,027.20. This trade represents a 27.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 19,657 shares of company stock valued at $326,586 over the last ninety days. 6.70% of the stock is currently owned by company insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.